Abbott Laboratories $ABT Shares Purchased by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC boosted its holdings in Abbott Laboratories (NYSE:ABT) by 272.4% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 118,698 shares of the healthcare product maker’s stock after buying an additional 86,827 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Abbott Laboratories were worth $14,872,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Charles Schwab Trust Co grew its position in Abbott Laboratories by 109.8% during the 3rd quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock worth $3,939,000 after purchasing an additional 15,394 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab purchased a new position in Abbott Laboratories during the 3rd quarter worth approximately $185,640,000. Asset Management One Co. Ltd. grew its position in Abbott Laboratories by 2.4% during the 3rd quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock worth $115,032,000 after purchasing an additional 19,966 shares in the last quarter. Nordea Investment Management AB grew its position in Abbott Laboratories by 6.1% during the 3rd quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock worth $43,785,000 after purchasing an additional 18,974 shares in the last quarter. Finally, AE Wealth Management LLC grew its position in Abbott Laboratories by 20.8% during the 3rd quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock worth $8,774,000 after purchasing an additional 11,264 shares in the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ABT. Citigroup lowered their price objective on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. Oppenheimer decreased their target price on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Daiwa Securities Group decreased their target price on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Raymond James Financial decreased their target price on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Finally, Evercore decreased their target price on shares of Abbott Laboratories from $138.00 to $134.00 and set an “outperform” rating for the company in a research note on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $134.58.

Abbott Laboratories Trading Up 1.8%

Shares of NYSE:ABT opened at $103.70 on Thursday. The firm has a fifty day moving average of $109.17 and a two-hundred day moving average of $120.35. The firm has a market capitalization of $180.61 billion, a P/E ratio of 27.88, a price-to-earnings-growth ratio of 1.64 and a beta of 0.79. Abbott Laboratories has a 12-month low of $100.88 and a 12-month high of $139.06. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. During the same quarter in the previous year, the business earned $1.34 EPS. Abbott Laboratories’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s payout ratio is presently 67.74%.

Insiders Place Their Bets

In related news, EVP Mary K. Moreland sold 613 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the sale, the executive vice president owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP John A. Jr. Mccoy sold 585 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the sale, the vice president directly owned 24,628 shares of the company’s stock, valued at approximately $2,846,504.24. The trade was a 2.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,055 shares of company stock worth $353,097 in the last 90 days. 0.46% of the stock is owned by corporate insiders.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Barclays raised its price target on ABT to $144 and keeps an “overweight” view, a bullish signal that likely helped buying interest. Abbott Laboratories price target raised by Barclays
• Positive Sentiment: Coverage highlighting Abbott as a “dividend king on sale” (value/dividend investors) increases interest from income-focused buyers given its long track record of payout consistency. A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?
• Neutral Sentiment: Several sell‑side analysts remain constructive (maintaining buy/outperform ratings) but trimmed targets modestly (Evercore to $134 from $138; BTIG similar), which is mixed news — keeps analyst support but reduces implied upside. Evercore ISI and BTIG Lower Abbott (ABT) Price Targets, Maintain Positive Ratings
• Neutral Sentiment: Analysts and media note the stock’s recent underperformance versus the broader market even as it edges up intraday — an important context for short‑term momentum traders. Abbott Laboratories stock rises Wednesday, still underperforms market
• Negative Sentiment: Goldman Sachs cut its price target sharply to $121 from $140 (still a “buy”), a downgrade in expectation that can pressure sentiment and cap near‑term gains. Goldman Sachs adjusts price target on Abbott Laboratories to $121 from $140; maintains buy rating
• Negative Sentiment: Analyses flag recent share weakness (down materially over the past 1–3 months) and fading momentum; fundamental concerns include a modest revenue shortfall in the last quarter despite EPS in line and only modest FY guidance — reasons some investors remain cautious. Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.